Atrial fibrillation (AF) is a leading cause of stroke. Oral anticoagulant (OAC) therapy can
significantly reduce the risk of stroke in patients with AF, but underuse of OACs for stroke …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …

ABSTRACT Introduction: Direct oral anticoagulants (DOACs) have emerged as alternatives
to vitamin K antagonists for the prevention of stroke in patients with non-valvular atrial …

Atrial fibrillation (AF) is strongly associated with cardioembolic stroke, and
thromboprophylaxis is an established means of reducing stroke risk in patients with AF. Oral …

Background and Purpose—The purpose of this study was to investigate the impact of
improved antithrombotic treatment in atrial fibrillation after the introduction of non–vitamin K …

Aims Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the
prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K …

For decades, warfarin has remained the standard oral anticoagulation for stroke prevention
in atrial fibrillation (AF). Three novel oral anticoagulants (NOACs) have been recently …

Background The risk of stroke associated with atrial fibrillation (AF) is higher in Far Eastern
population than in Western population, and warfarin use suboptimal. There is uncertainty …

Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …